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ohn J. Mahmarian, MD,* Habib A. Dakik, MD,† Neil G. Filipchuk, MD,‡ Leslee J. Shaw, PHD,§
herif S. Iskander, MD, Terrence D. Ruddy, MD,¶ Felix Keng, MD,# Milena J. Henzlova, MD,**
del Allam, MD,†† Lemuel A. Moyé, MD, PHD,‡‡ Craig M. Pratt, MD,* for the INSPIRE Investigators
ouston and Tyler, Texas; Beirut, Lebanon; Calgary and Ottawa, Canada; Los Angeles, California; Singapore;
ew York, New York; and Cairo, Egypt
OBJECTIVES The purpose of this study was to determine the relative benefit of intensive medical therapy
compared with coronary revascularization for suppressing scintigraphic ischemia.
BACKGROUND Although medical therapies can reduce myocardial ischemia and improve patient survival after
acute myocardial infarction, the relative benefit of medical therapy versus coronary revascu-
larization for reducing ischemia is unknown.
METHODS A prospective randomized trial in 205 stable survivors of acute myocardial infarction was
made to define the relative efficacy of an intensive medical therapy strategy versus coronary
revascularization for suppressing scintigraphic ischemia as assessed by serial gated adenosine
Tc-99m sestamibi myocardial perfusion tomography. All patients at baseline had large total
(20%) and ischemic (10%) adenosine-induced left ventricular perfusion defects and an
ejection fraction 35%. Imaging was performed during 1 to 10 days of hospital admission
and repeated in an identical fashion after optimization of therapy. Patients randomized to
either strategy had similar baseline demographic and scintigraphic characteristics.
RESULTS Both intensive medical therapy and coronary revascularization induced significant but
comparable reductions in total (16.2  10% vs. 17.8  12%; p  NS) and ischemic (15
 9% vs. 16.2  9%; p  NS) perfusion defect sizes. Likewise, a similar percentage of
patients randomized to medical therapy versus coronary revascularization had suppression of
adenosine-induced ischemia (80% vs. 81%; p  NS).
CONCLUSIONS Sequential adenosine sestamibi myocardial perfusion tomography can effectively monitor
changes in scintigraphic ischemia after anti-ischemic medical or coronary revascularization
therapy. A strategy of intensive medical therapy is comparable to coronary revascularization
for suppressing ischemia in stable patients after acute infarction who have preserved LV
function. (J Am Coll Cardiol 2006;48:2458–67) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.068Cardiology Foundation
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Advances in medical management have greatly
improved patient outcome after acute myocar-
dial infarction (AMI). Beta-blockers (BB) (1),
angiotensin-converting enzyme (ACE) inhibi-
tors (2), antiplatelet agents (3), statins (4), and
certain rate-lowering calcium-channel blockers
CCB) (5) benefit patients through their targeted effects on
hrombus formation (6,7), plaque progression (8), myocar-
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Manuscript received March 30, 2006; revised manuscript received July 5, 2006,
ccepted July 6, 2006.ial ischemia (9), and left ventricular (LV) dysfunction and
emodeling (10). However, despite this extensive trial-based
vidence, coronary revascularization is generally considered
he preferred treatment for patients after AMI, particularly
hen there is extensive coronary artery disease (CAD) on
ngiography or substantial myocardial ischemia detected by
oninvasive testing. Prospective randomized trials directly
omparing an optimal medical with a coronary revascular-
zation strategy in patients with objective evidence of
schemia are limited (9,11–13).
See page 2468
The INSPIRE (Adenosine Sestamibi Post-Infarction
valuation) is a prospective multicenter trial designed to
efine the role of adenosine Tc-99m sestamibi single-
hoton emission computed tomography (ADSPECT) for
tratifying patient risk based on scintigraphic variables and
V ejection fraction (EF) (14,15). Its other main objective
s to compare the relative efficacy of an initial intensive
edical therapy strategy to one of coronary revascularization
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table but high-risk cohort of the INSPIRE trial (14,15).
denosine SPECT was chosen as the imaging method
ecause it is a safe and reliable (15) technique for detecting
cintigraphic ischemia early after AMI. The INSPIRE
tudy was designed based on a previous exploratory pilot
tudy in AMI patients which suggested that intensive
edical therapy equaled percutaneous coronary intervention
PCI) for suppressing ischemia as assessed by sequential
denosine SPECT performed before and after therapy (9).
ETHODS
tudy population. Of the 728 patients enrolled in the
NSPIRE trial, 205 had a large total (20%) and ischemic
10%) LV perfusion defect size (PDS) and an LV EF
35% by adenosine SPECT and form the basis of this
able 1. INSPIRE Inclusion and Exclusion Criteria (14)
nclusion criteria
1. Chest pain 30 min duration with
a. ST-segment elevation or depression (0.1 mV) in
2 consecutive ECG leads and a rise in cardiac enzymes
 twice the upper limit of normal
OR
b. ST-segment elevation (0.1 mV) in 2 consecutive ECG leads
with development of diagnostic Q waves
2. Age 18 yrs
3. Total perfusion defect size 20%, ischemic defect size 10%, and
left ventricular ejection fraction 35%*
xclusion criteria
1. Cardiogenic shock
2. Recurrent chest pain unresponsive to anti-ischemic medications
requiring emergency revascularization
3. Uncompensated congestive heart failure
4. Sustained ventricular tachycardia or fibrillation after the first 24 h
5. Acute coronary angiography with primary percutaneous coronary
intervention
6. Left bundle branch block on initial 12-lead ECG
7. Contraindication to adenosine
8. Concomitant noncardiac illness that would limit 1-yr follow-up
9. Premenopausal women unless documented not to be pregnant
10. Inability to give informed consent
Abbreviations and Acronyms
ADSPECT  adenosine technetium-99m sestamibi
single-photon emission computed
tomography
AMI  acute myocardial infarction
BB  beta-blockers
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CCB  calcium-channel blocker
EF  ejection fraction
LAD  left anterior descending
LV  left ventricular
PCI  percutaneous coronary intervention
PDS  perfusion defect sizet
For randomization.
ECG  electrocardiogram/electrocardiographic.eport (14,15). Although clinically stable, these patients
ere considered to be at high risk for subsequent cardiac
vents based on their scintigraphic profile (15). Inclusion
nd exclusion criteria for entry into the INSPIRE trial are
hown in Table 1.
tudy design. The research protocol was approved at each
ite by their respective institutional review boards, and all
atients gave written informed consent. The INSPIRE
tudy design is published (14). Patients underwent standard
ated rest-stress adenosine SPECT within 10 days of
ospital admission with quantification of total and ischemic
V PDS and LV EF (14,15). Those meeting entry criteria
ere randomized to either an initial strategy of intensive
nti-ischemic medical therapy (strategy 1) or coronary
ngiography with the intent to revascularize (strategy 2). A
econd scan (SPECT 2) was performed a median of 62 days
fter optimizing therapy. Images were quantified by the core
aboratory blinded to treatment allocation. Patients were
ollowed 1 year, and all cardiac events were adjudicated by
n end point committee (14,15).
edical therapy group (strategy 1). Patients randomized
o strategy 1 were not to have coronary angiography unless
able 2. Medication Ranking for Determining the Intensity of
edical Therapy
Total Daily Dose (mg)
Low Medium High
ong-acting nitrates
Nitrodur (mg/h) 0.2 0.2–0.4 0.5
Isosorbide mononitrate 30 31–60 61
Isosorbide dinitrate 30 31–60 61
eta-blockers
Atenolol 25 50–75 76
Metoprolol 50–75 76–125 126
Propranolol 80 81–159 160
Sotalol 80 81–239 240
Carvedilol 12.5 12.6–37.5 37.5
Bisoprolol 5 6–14 15
CE inhibitors/ARBs
Accupril 10 11–20 21
Enalapril 10 11–20 21
Lisinopril 10 11–20 21
Monopril 10 11–20 21
Ramapril 2.5 2.6–5 5
Irbesartan 150 150–300 300
Captopril 20 20–75 76
Losartan 50 51–99 100
alcium-channel blockers
Diltiazem 120 121–240 241
Amlodipine 2.5 2.6–7.5 7.6
ipid-lowering drugs
Lipitor 20 21–40 40
Fluvastatin 40 40–60 60
Pravastatin 40 40–60 60
Simvastatin 30 31–60 60
Fenofibrate 54 55–160 160
Gemfibrozil 600 601–1,200 1,200
CE  angiotensin-converting enzyme; ARB  angiotensin II receptor antagonist.hey developed clinical instability (14). Medical therapy was
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Medical Therapy for Reducing Myocardial Ischemia December 19, 2006:2458–67itrated to maximally tolerated doses over 4 to 8 weeks using
redefined recommended algorithms (14).
Intensity of medical therapy was based on a relative
anking of medications by drug class (Table 2). Total daily
rug dosages were classified as: none 0, low 1, medium
, or high  3. The intensity of medical therapy was
alculated by adding the dose classification (0 to 3) of each
nti-ischemic medication (i.e., BB, CCB, long-acting ni-
rates) and defined as low (0 to 3), medium (4 to 6), or high
7 to 9). A crossover occurred when a patient randomized to
edical therapy had revascularization before SPECT 2.
evascularization group (strategy 2). Patients random-
zed to strategy 2 were encouraged to have coronary angiog-
aphy followed by PCI or coronary artery bypass graft
urgery (CABG). Specific treatment recommendations are
hown in Table 3. A crossover in this strategy was defined
s any patient who did not undergo revascularization before
PECT 2.
tatistical analysis. The statistical analysis plan is pub-
ished (14). The primary end point of the INSPIRE trial
as to determine the relative efficacy of an initial intensive
edical therapy strategy (strategy 1) compared with one of
oronary revascularization (strategy 2) for reducing total and
schemic LV PDS. The sample size for detecting a thera-
eutic difference in scintigraphic parameters between the 2
andomized groups was based on a previous reproducibility
tudy (16). With 169 patients, there was 80% power ( 
.05) to detect a 4% absolute difference between treatment
roups (14).
Chi-square or t test statistics were used to compare
aseline characteristics between randomized groups and
etect differences in patients who did or did not have 2
PECT studies. All comparisons were reported by fre-
uency (%) or mean  standard deviation. Chi-square
nalysis compared the type and intensity of medical therapy
sed and the percentage of patients who had a 9% change
n total and ischemic PDS in each strategy. The percentage
hange in total, ischemic, and scar PDS and LV EF were
able 3. Therapeutic Considerations for Patients Randomized
o Strategy 2 (14)
. Coronary artery bypass surgery was recommended over percutaneous
coronary intervention in patients with
a. 50% left main stenosis
b. 3-vessel coronary artery disease
c. Diabetes and multivessel disease
. Patients undergoing coronary artery bypass surgery were encouraged
to have grafting of all arteries with significant (50%) stenosis as
deemed technically feasible
. Patients undergoing percutaneous coronary intervention were
encouraged to have dilation and stenting of the infarct-related artery
and any other artery with significant (50%) stenosis
. Anti-ischemic medical therapy as proposed in strategy 1 was
recommended for patients who
a. Were not revascularized,
b. Had residual angina following revascularization, or
c. Had incomplete revascularizationompared by strategy using analysis of variance techniques. laired t tests compared total, ischemic, and scar PDS and
V EF at SPECT 1 and 2.
A secondary observational end point was to compare time
o first cardiac event in the 2 strategies using Kaplan-Meier
stimates and Cox proportional hazards regression (14).
he power of this analysis was30%. All analyses are based
n intention-to-treat.
ESULTS
aseline characteristics. The baseline characteristics of
he 2 randomized groups were well matched (Table 4). Of
he 205 randomized patients, 36 (18 patients/group) were
xcluded from primary end point analysis for the following
easons: terminated study participation before SPECT 2
n  12); refused repeat imaging (n  8); lost to follow-up
n  7); expired after the first study (n  5) with 1 cardiac
eath within strategy 1 and 2 within strategy 2; side effects
o adenosine (n  2); and poor-quality images (n  2).
aseline clinical characteristics were not significantly differ-
nt between those who did or did not have SPECT 2. Their
nitial scintigraphic profile, overall subsequent treatment,
nd clinical outcome were also similar (Table 5).
rossover between strategies. The crossover rates be-
ween treatment strategies were comparable: 26 out of 101
trategy 1 patients (25.7%) were revascularized, and 24 out
f 104 strategy 2 patients (23.1%) defaulted to medical
herapy. Nine out of 26 (35%) patients who crossed from
trategy 1 to strategy 2 did so outside of protocol owing to
hysician and/or patient preference rather than a clinically
ndicated reason. Although most patients had minimal or
o angina during the therapy titration phase before SPECT
(74%), those who crossed over in either strategy more
requently had anginal episodes (37%) than those who did
ot (22%; p  0.52).
nti-ischemic medical therapy. Patients in both random-
zed limbs received medical therapy, although those in
trategy 1 more frequently received a CCB, long-acting
itrate, and ACE inhibitor than those in strategy 2 (Table
). Most patients (70%) in strategy 1 were on 2 anti-
schemic medications at the time of SPECT 2 versus 36% in
trategy 2 (p 0.05) (Table 6). Likewise, 60% of patients in
trategy 1 were taking a medium (49%) or high (11%)
ntensity of medications versus 21% and 6% of patients,
espectively, in strategy 2 (p  0.05).
oronary revascularization. Within strategy 2, 83 out of
6 patients who had serial SPECT underwent coronary
ngiography (97%), of whom 25 had single-vessel, 25 had
ouble-vessel, and 33 had triple-vessel CAD. Twelve pa-
ients had concomitant left main stenosis.
Seventy out of 86 patients randomized to strategy 2 (81%)
ere revascularized (Table 7). Coronary artery bypass graft-
ng (CABG) was performed in 27 patients: 21 with triple-
essel, 5 with double-vessel, and 1 with single-vessel CAD.
he internal mammary artery was used to graft 23 out of 25eft anterior descending (LAD) coronary arteries. Saphe-
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December 19, 2006:2458–67 Medical Therapy for Reducing Myocardial Ischemiaous vein grafts were placed in 2 LAD, 22 right, 19
ircumflex, 2 ramus, and 7 diagonal arteries. A PCI was
erformed in 43 patients with dilation of the LAD in 9,
ight in 22, circumflex in 19, and ramus arteries in 2
atients. Most (85%) revascularized patients with single- (n
20) or double-vessel (n  21) CAD had PCI (95% and
6%, respectively) rather than CABG (15%). Stents were
laced in 49 of 52 dilated arteries (94%) and 44% of patients
lso received a glycoprotein IIb/IIIa antagonist. In total,
9% of arteries with 50% and 71% with 70% stenosis
ad successful revascularization. In the 70 revascularized
atients, this increased to 80% and 83%, respectively.
Twenty of 21 patients (95%) in strategy 1 who had serial
PECT and underwent revascularization had multivessel
AD. A CABG was performed in 2 patients with double-
essel and 8 patients with triple-vessel CAD. Eleven pa-
ients had PCI with stents placed in 11 out of 12 (92%)
ilated arteries. Sixty-eight percent of arteries with 50%
tenosis and 78% of those with 70% stenosis were revas-
ularized (Table 7).
rimary end point: group adenosine SPECT results. In the
69 patients who had serial SPECT imaging, the overall total
able 4. Baseline Characteristics for the Total Study Population
Strategy 1
(Medical The
(n  101
ge (yrs)* 64  11
omen (%) 22
ypertension (%, BP 140/90 mm Hg) 64
iabetes (%) 26
amily history of CAD (%) 30
yperlipidemia (%) 69
moking history (%) 54
rior CAD (%) 33
rior AMI (%) 21
illip class (%)
I 64
II 12
III–IV 24
T-segment elevation AMI (%) 54
-wave AMI (%) 47
MI location (%)
Anterior 26
Inferior 49
Lateral 9
Posterior 1
Other 15
hrombolytic therapy (%) 34
IMI risk score
Low (0–2) 51
Intermediate (3–5) 33
High (6) 16
otal PDS (% LV)* 32.7  11
car PDS (% LV)* 10.7  8
schemia PDS (% LV)* 22.0  10
VEF (%)* 49  9
Mean  standard deviation.
AMI  acute myocardial infarction; BP  blood pressure; CAD  coronary arter
efect size; TIMI  Thrombolysis In Myocardial Infarction.V PDS decreased from 33.1  8.9% to 16.1  11% (p  1.0001) (Fig. 1). The reduction in total PDS was almost
ntirely attributable to the reduction in ischemic PDS from 22
7.1% to 6.4  6.2% (p  0.0001).
The serial SPECT comparison between the 2 random-
zed groups is the primary study end point (Table 8).
atients in strategy 1 and strategy 2 showed highly significant
p  0.001) but comparable (p  NS) reductions in total
16.2 10% vs.17.8 12%) and ischemic (15 9% vs.
16.2  9%) LV PDS with minimal absolute scintigraphic
reatment differences between strategies (1.6  11% for
otal PDS; 1.2  9% for ischemic PDS).
ndividual adenosine SPECT results. A 9% serial
hange in PDS represents a true individual patient change
eyond technique variability (16). Consistent with mean
roup results, a comparable percentage of strategy 1 and
trategy 2 patients had a significant reduction in total (75%
s. 79%) and ischemic (80% vs. 81%) PDS and achieved a
ow-risk (20%) total PDS on SPECT 2 (64% vs. 69%; p
0.51) (16) (Table 8, Fig. 2). Figure 3 is a representative
xample.
ardiac events. Cardiac events occurred in 15 out of 101
atients randomized to strategy 1 (14.8%) and in 13 out of
Strategy 2
(Revascularization Therapy)
(n  104) p Value
63  12 0.49
27 0.39
49 0.03
31 0.42
25 0.45
62 0.24
57 0.64
23 0.13
14 0.23
0.69
69
9
22
48 0.39
38 0.19
0.08
18
38
18
3
23
27 0.29
0.12
50
42
8
32.6  10 0.99
12  8 0.21
20.6  8 0.62
47  9 0.11
se; LV  left ventricle; LVEF  left ventricular ejection fraction; PDS  perfusionrapy)
)04 randomized to strategy 2 (12.5%) (2.4%, 95% CI

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Medical Therapy for Reducing Myocardial Ischemia December 19, 2006:2458–677.1 to 11.8%; p  NS), with a comparable incidence of
eath/nonfatal reinfarction (8 out of 101 or 7.9% vs. 7 out
f 104 or 6.7%; 1.2%, 95% CI 5.9 to 8.3%; p  NS)
Fig. 4). By multivariate analysis, diabetes mellitus (p 
.02), total PDS (p  0.04), and scar PDS (p  0.04)
redicted subsequent outcome.
ISCUSSION
he INSPIRE study is the first large prospective randomized
rial to describe the relative effects of intensive medical therapy
ersus coronary revascularization on scintigraphic ischemia
Table 5. Comparison Between Patients Who D
Scintigraphic profile
Total PDS (% LV)
Ischemic PDS (% LV)
LVEF (%)
Medical therapy received
Aspirin/clopidogrel
Beta-blocker
Lipid therapy
Calcium-channel blocker
Long-acting nitrate
ACE inhibitor
Total number of anti-ischemic medications*
0
1
2
3
Crossover between strategies
% revascularized
Overall events
Death/AMI
*Beta-blocker, long-acting nitrate, calcium-channel blocker.
ACE  angiotensin-converting enzyme; AMI  acute m
ejection fraction; PDS  perfusion defect size; SPECT  s
able 6. Medical Therapy Administered to Patients in Both Stra
Total Randomized Pati
Strategy 1
(Medical Therapy)
(n  83)
Strategy
(Revasculariz
Therapy) (n 
spirin/clopidogrel 83/83 (100%) 82/86 (95%
eta-blocker 77/83 (93%) 74/86 (86%
ipid therapy 70/83 (84%) 66/86 (77%
alcium-channel blocker 35/83 (42%) 17/86 (20%
ong-acting nitrate 47/83 (57%) 27/86 (31%
CE inhibitor 64/83 (77%) 49/86 (57%
otal anti-ischemic drugs,†
0 3/83 (3%) 10/86 (12%
1 22/83 (27%) 45/86 (52%
2 37/83 (45%) 20/86 (23%
3 21/83 (25%) 11/86 (13%
ntensity of medical therapy†
Low (0–3) 33/83 (40%) 63/86 (73%
Medium (4–6) 41/83 (49%) 18/86 (21%
High (7–9) 9/83 (11%) 5/86 (6%Minus crossovers. †Long-acting nitrate, beta-blocker, calcium-channel blocker.
ACE  angiotensin-converting enzyme; SPECT  single-photon emission computedsing serial adenosine SPECT imaging and specifically within
linically stable but high-risk patients after AMI. Our results
emonstrate that an initial strategy of intensive medical ther-
py suppresses ischemia to a degree comparable to that
chieved with revascularization in addition to standard medical
herapy. Furthermore, ischemia suppression was achieved in
80% of patients randomized to either strategy. Consistent
ith the similarity in scintigraphic treatment effects, 1-year
ardiac event rates were comparable between strategies. The
esults from INSPIRE are similar to those reported in our
riginal small pilot study (9) and indicate that serial SPECT
r Did Not Have Repeat SPECT
SPECT
 169)
No 2nd SPECT
(n  36) p Value
.1  11% 30.8  9% 0.24
.0  9% 18.1  8% 0.02
.1  9% 48.8  8% 0.67
65 (98%) 34 (94%) 0.30
51 (89%) 27 (75%) 0.02
36 (80%) 26 (72%) 0.27
52 (31%) 11 (31%) 0.98
74 (44%) 18 (50%) 0.50
13 (67%) 23 (64%) 0.73
13 (8%) 5 (14%) 0.18
67 (39%) 10 (28%)
57 (34%) 17 (47%)
32 (19%) 4 (11%)
37 (22%) 13 (36%) 0.07
91 (54%) 15 (42%) 0.18
22 (13%) 6 (17%) 0.56
10 (6%) 5 (14%) 0.10
ial infarction; LV  left ventricle; LVEF  left ventricular
hoton emission computed tomography.
s Who Had Two SPECT Studies
Per Protocol*
p Value
Strategy 1
(Medical Therapy)
(n  62)
Strategy 2
(Revascularization
Therapy) (n  70) p Value
0.12 62/62 (100%) 68/70 (97%) 0.5
0.21 57/62 (92%) 59/70 (84%) 0.2
0.25 51/62 (82%) 54/70 (77%) 0.52
0.01 30/62 (48%) 11/70 (16%) 0.001
0.001 41/62 (66%) 14/70 (20%) 0.001
0.01 46/62 (74%) 41/70 (59%) 0.07
0.001 0.001
2/62 (3%) 9/70 (13%)
10/62 (16%) 43/70 (61%)
32/62 (52%) 13/70 (19%)
18/62 (29%) 5/70 (7%)
0.001 0.001
19/62 (31%) 57/70 (82%)
35/62 (56%) 10/70 (14%)
8/62 (13%) 3/70 (4%)id o
2nd
(n
33
22
48
1
1
1
1tegie
ents
2
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)
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December 19, 2006:2458–67 Medical Therapy for Reducing Myocardial Ischemiaan effectively track the effects of medical and revascularization
herapies on scintigraphic ischemia. In this regard, intensive
edical therapy alone may be a reasonable treatment alterna-
ive in stable patients after AMI who have ischemia but are not
ptimal revascularization candidates.
reatment strategies in the INSPIRE trial. The inten-
ion of the INSPIRE trial was to randomize patients to
eceive either protocol-directed optimal medical therapy
itrated to maximally tolerated doses, or state-of-the-art
nterventional approaches with additional medical therapy
s clinically indicated. Patients randomized to strategy 1
ntered a dose titration phase to ensure they would receive
aximally tolerated medical therapy before SPECT 2.
ccordingly, most patients in strategy 1 were on BB (93%),
CE inhibitors (77%), and lipid-lowering medications
84%), with approximately half also receiving a long-acting
itrate and CCB. The type and intensity of medical therapy
rescribed in the INSPIRE trial is consistent with contem-
orary guidelines for patients recovering from AMI (14).
In patients randomized to strategy 2, 81% were revascu-
arized before SPECT 2, a rate similar to that reported in
ther AMI (17) and acute coronary syndrome (18) trials. In
ccordance with accepted guidelines, most patients with left
ain or 3-vessel CAD underwent CABG, with PCI and
igure 1. Absolute mean ( SD) change in scintigraphic variables in 169
andomized patients who had 2 adenosine single-photon tomographic
Table 7. Coronary Revascularization Results B
to Strategy 2 Who Had Two SPECT Studies
Total Strategy 2 Patients (
>50% Stenosis >70%
Artery
Left main 10/12 (83%)
LAD 34/47 (72%) 33
RCA 44/61 (72%) 42
Cx 38/54 (70%) 38
Ramus 4/9 (44%)
Diagonal 7/17 (40%) 6
Total 137/200 (69%) 130/1
Major arteries* 126/174 (72%) 120/1
*Left main, LAD, RCA, Cx.
Cx  circumflex; LAD  left anterior descending; RC
computed tomography.I
SPECT) studies. LV  left ventricle; LVEF  left ventricular ejection
raction; PDS  perfusion defect size.oncomitant arterial stenting reserved for patients with less
xtensive involvement. The goal of INSPIRE to achieve
igh revascularization rates among patients assigned to this
trategy was met in that most arteries (83%) with 70%
tenosis were revascularized with stents placed in over 90%
f dilated arteries.
schemia suppression with medical therapy. The sub-
tantial suppression of stress-induced scintigraphic ischemia
ith medical therapy alone may seem surprising, but is
onsistent with findings from earlier small reports in pa-
ients with chronic CAD (19). This beneficial effect on
yocardial perfusion may be explained by a selective in-
rease in coronary flow reserve within vascular territories
upplied by stenosed coronary arteries, which results in more
omogeneous myocardial perfusion during stress and there-
ore a smaller PDS. Resting myocardial blood flow is
referentially increased within initially ischemic areas by BB
19,20) and long-acting nitrates (21), thereby limiting the
eed for further arteriolar vasodilation to support resting
ow and allowing an enhanced increase in flow during
tress. Beta-blockers also improve myocardial efficiency by
educing oxygen demands and metabolic oxidative metab-
lism (22). Nitrates exert their beneficial effects through
reload reduction, enhanced recruitment of collaterals (23),
nd/or epicardial arterial vasodilation (24). Statins improve
ndothelial dysfunction as their probable mechanism for
cintigraphic benefit (25). The substantial reductions in
cintigraphic ischemia we report with medical therapy may
elp explain the known beneficial effects of BB (1), statins
4), and certain CCB (5) for reducing cardiac events in
atients recovering from AMI.
revious studies. Few randomized prospective trials have
ddressed the relative clinical benefit of medical therapy
ersus coronary revascularization (9,11–13,26–29), and of
hese most have not focused on patients with AMI
11,12,27–29), none achieved the uniformly intensive med-
cal therapy regimen reported in INSPIRE, and only 1
howed an advantage of revascularization over medical
herapy for improving infarct-free survival (13). The
on Stenosis Severity in Patients Randomized
86) Patients Revascularized (n  70)
osis >50% Stenosis >70% Stenosis
8%) 10/11 (91%) 7/7 (100%)
7%) 34/40 (85%) 33/38 (87%)
4%) 44/54 (81%) 42/51 (82%)
5%) 37/45 (82%) 37/42 (88%)
0%) 4/7 (57%) 4/6 (67%)
0%) 7/14 (50%) 6/12 (50%)
1%) 136/171 (80%) 129/156 (83%)
5%) 125/150 (83%) 119/138 (86%)
right coronary artery; SPECT  single-photon emissionased
n 
Sten
7/8 (8
/43 (7
/57 (7
/51 (7
4/8 (5
/15 (5
82 (7
59 (7NSPIRE trial results are similar to those reported in our initial
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schemic (12  10% vs. 12  9%) PDS were comparably
educed with medical therapy and PCI (9). Of note, despite a
-fold increase in sample size, medical and interventional
reatment effects remained as variable in INSPIRE as in the
ilot study, with only 67% of patients decreasing their total
DS to a low-risk value of 20% (15). Thus, although each
herapy comparably reduces the extent of scintigraphic isch-
mia within populations, there is significant individual patient
eterogeneity in these treatment effects.
linical relevance of the INSPIRE trial. What conclu-
ions should we reach from this randomized trial? The
NSPIRE study was novel in randomizing AMI patients
ith a high-risk scintigraphic profile to medical therapy
nd then optimizing treatment as mandated by study
esign. Both randomized groups had similar reductions
n scintigraphic ischemia and comparable cardiac event
ates, thus challenging the conventional assumption that
able 8. Primary End Point: Gated SPECT Results: Strategy 1 V
Strategy 1
(Medical Therapy)
(n  83)
otal LV PDS (absolute % change) 16.2  10 (35.8 to 3.4)
schemic LV PDS (absolute % change) 15.0  9 (32.6 to 2.6)
car LV PDS (absolute % change) 1.2  8 (16.9 to 14.5)
patients 9% decrease
Total LV PDS 75%
Ischemic LV PDS 80%
V EF (absolute % change) 4.7  7
5% confidence intervals in parentheses.
EF  ejection fraction; LV  left ventricular; PDS  perfusion defect size; SPE
igure 2. Primary end point: absolute mean ( SD) and individual chang
PECT-1 to SPECT-2 study in the 2 randomized groups. The dashed line r
atient change). Other abbreviations as in Figure 1.n invasive strategy is superior to one of intensive medical
herapy. The clinical lesson from the INSPIRE trial is
ot that this trial was unable to statistically detect the
bserved 1.2% difference in ischemia suppression be-
ween treatment strategies, but rather that this difference
s so small and well within the variability reported with
equential SPECT imaging (16). An adequately powered
ardiac event trial emulating the INSPIRE study design
ould best clarify whether such small relative scinti-
raphic improvements translate into clinical benefit
14,15). Although our reported event rates between
trategies are not conclusive, they do provide ample
reliminary data to design such a study. Strong support
or the clinical relevance of INSPIRE comes from a
ecent large cohort study of 158,831 Medicare patients
ollowed 7 years after AMI (30), where a routine invasive
pproach did not improve survival beyond that seen with
tandard medical management. Like the INSPIRE trial,
s Strategy 2 Patients
Strategy 2
evascularization Therapy)
(n  86) p Value
Difference in
Treatment Effect
Strategy 1 vs. Strategy 2
17.8  12 (41.3 to 5.7) 0.36 1.6  11 (20.0 to 23.3)
16.2  9 (33.8 to 1.4) 0.44 1.2  9 (16.4 to 18.8)
1.6  7 (15.3 to 12.1) 0.73 0.4  7 (14.3 to 15.1)
79% 0.50
81% 0.76
4.6  8 0.93
single-photon emission computed tomography.
total and ischemic left ventricular (LV) perfusion defect size (PDS) fromersu
(R
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es in
epresents a 9% reduction in PDS (i.e., 95% confidence interval for a real
t
o
r
S
t
c
g
b
c
a
p
p
F
i
I
t ECT
a
2465JACC Vol. 48, No. 12, 2006 Mahmarian et al.
December 19, 2006:2458–67 Medical Therapy for Reducing Myocardial Ischemiahose results suggest that intensive medical management
f ischemia is an acceptable alternative to coronary
evascularization.
tudy limitations. The INSPIRE study was designed before
he use of drug-eluting stents which reduce the incidence of
oronary restenosis (31). However, it is unlikely that newer-
igure 3. Serial SPECT images and polar plot of a patient randomized to
n the short (SA), horizontal long (HLA), and vertical long (VLA) axis slic
schemia is present in the right and circumflex vascular territories. Total LV
reated with a beta-blocker, calcium-channel blocker, and statin. Repeat SP
bbreviations as in Figure 1.Figure 4. Patient outcome based oneneration stents would have changed our scintigraphic results,
ecause serial imaging was performed before the typical time
ourse of restenosis (32). We studied a stable cohort of patients
fter AMI who had significant scintigraphic ischemia but
reserved LV function. Our results may not be applicable to
atients who are clinically unstable or have poor LV function.
cal therapy. Baseline SPECT (A) shows a large perfusion defect (arrows)
er stress (upper panels) which improves with rest imaging (lower panels).
S is 30% with 25% ischemia (green) and 5% scar (black). The patient was
(B) is entirely normal. This patient had no subsequent cardiac event. Othermedi
es aft
PDrandomized treatment strategy.
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ntent to revascularize and therefore were not considered
ppropriate for randomization. In the main INSPIRE trial,
atients with ischemia and an LV EF 35% were routinely
eferred for an invasive evaluation (14,15). Serial SPECT was
ot performed in 36 patients, but generally for noncardiac
easons. It is unlikely that these patients would have altered our
rimary end point results, because they were evenly distributed
cross both treatment strategies, had similar baseline charac-
eristics, and received comparable therapy. Finally, the cross-
ver rate was approximately 25% in both randomized groups.
s in all clinical trials assessing a treatment strategy, the
NSPIRE trial explored the relative benefit of each strategy on
he primary end point based on initial randomized treatment
llocation. The crossover rates in the INSPIRE trial are
enerally lower than reported in other clinical event trials
tudying similar patients (18,33).
onclusions. Sequential ADSPECT can effectively monitor
hanges in scintigraphic ischemia following either medical or
nterventional therapies. An initial strategy of intensive medical
herapy suppresses ischemia to an extent comparable to coro-
ary revascularization when combined with standard medical
herapy and may therefore be a reasonable treatment alterna-
ive in stable patients after AMI who have preserved LV
unction but are not optimal revascularization candidates. This
herapeutic approach is best further explored in an adequately
owered outcome trial studying patients similar to those
andomized in the INSPIRE trial.
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